Journal article
Effects of menopausal hormone therapy on erythrocyte n–3 and n–6 PUFA concentrations in the Women’s Health Initiative randomized trial
The American journal of clinical nutrition, Vol.113(6), pp.1700-1706
06/2021
DOI: 10.1093/ajcn/nqaa443
PMCID: PMC8168349
PMID: 33710263
Abstract
The factors other than dietary intake that determine tissue concentrations of EPA and DHA remain obscure. Prior studies suggested that, in women, endogenous estrogen may accelerate synthesis of DHA from ɑ-linolenic acid (ALA), but the effects of exogenous estrogen on RBC n–3 (ɷ-3) PUFA concentrations are unknown.
We tested the hypothesis that menopausal hormone therapy (HT) would increase RBC n–3 PUFA concentrations.
Postmenopausal women (ages 50–79 y) were assigned to HT or placebo in the Women’s Health Initiative (WHI) randomized trial. The present analyses included a subset of 1170 women (ages 65–79 y) who had RBC PUFA concentrations measured at baseline and at 1 y as participants in the WHI Memory Study. HT included conjugated equine estrogens (E) alone for women without a uterus (n = 560) and E plus medroxyprogesterone acetate (P) for those with an intact uterus (n = 610). RBC n–3 and n–6 (ɷ-6) PUFAs were quantified.
Effects of E alone and E+P on PUFA profiles were similar and were thus combined in the analyses. Relative to the changes in the placebo group after 1 y of HT, docosapentaenoic acid (DPA; n–3) concentrations decreased by 10% (95% CI: 7.3%, 12.5%), whereas DHA increased by 11% (95% CI: 7.4%, 13.9%) in the HT group. Like DHA, DPA n–6 increased by 13% from baseline (95% CI: 10.0%, 20.3%), whereas linoleic acid decreased by 2.0% (95% CI: 1.0%, 4.1%; P values at least <0.01 for all). EPA and arachidonic acid concentrations were unchanged.
HT increased RBC concentrations of the terminal n–3 and n–6 PUFAs (DHA and DPA n–6). These findings are consistent with an estrogen-induced increase in DHA and DPA n–6 synthesis, which is consistent with an upregulation of fatty acid elongases and/or desaturases in the PUFA synthetic pathway. The clinical implications of these changes require further study. The Women’s Health Initiative Memory Study is registered at clinicaltrials.gov as NCT00685009. Note that the data presented here were not planned as part of the original trial, and therefore are to be considered exploratory.
▪
Details
- Title: Subtitle
- Effects of menopausal hormone therapy on erythrocyte n–3 and n–6 PUFA concentrations in the Women’s Health Initiative randomized trial
- Creators
- William S Harris - University of South DakotaNathan L Tintle - Dordt UniversityJoAnn E Manson - Harvard UniversityAdam H Metherel - University of TorontoJennifer G Robinson - Department of Epidemiology, College of Public Health, Iowa City, IA, USA
- Resource Type
- Journal article
- Publication Details
- The American journal of clinical nutrition, Vol.113(6), pp.1700-1706
- Publisher
- Elsevier Inc
- DOI
- 10.1093/ajcn/nqaa443
- PMID
- 33710263
- PMCID
- PMC8168349
- ISSN
- 0002-9165
- eISSN
- 1938-3207
- Grant note
- DOI: 10.13039/100000050, name: National Heart, Lung, and Blood Institute, award: BAA 19
- Language
- English
- Date published
- 06/2021
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984363628802771
Metrics
6 Record Views